In preclinical studies, ALK-04 demonstrated significant therapeutic potential by synergistically reducing melanoma tumor growth when combined with GVAX/anti-PD-1 immunotherapy via MCT4/SLC16A3 axis (182). Here, SLC16A3 is linked to neoplasm.